A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab

NCT07268521 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Cryoglobulinemic Vasculitis (CV)

Interventions

DRUG: Obinutuzumab

Sponsor

Assistance Publique - Hôpitaux de Paris